FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Released May 17, 2017
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Released May 17, 2017
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Released May 17, 2017
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Evaluating Sleep Deprivation as a Risk Factor for Postpartum Depression
Diagnosing and Treating Benign Prostatic Hyperplasia and Overactive Bladder
Bladders, Breakthroughs, and Bold New Therapies: Key Updates at AUA 2025
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Stay current with the best on medical education